Public consultation open on equitable access to medicines for the treatment of obesity

Page last updated: 5 September 2025

On 6 March 2025, the Minister for Health, Disability and Ageing, Hon Mark Butler MP, wrote to the Chair of the Pharmaceutical Benefits Advisory Committee (PBAC) to seek the committee’s advice on equitable access to glucagon-like peptide-1 receptor agonist (GLP-1) medicines for the treatment of obesity through the Pharmaceutical Benefits Scheme (PBS). The PBAC will consider this item at the November 2025 PBAC meeting (November 2025 PBAC agenda).

Public consultation on items to be considered by the PBAC in November 2025 is open to 24 September 2025, through the Office of Health Technology Assessment Consultation Hub.

If you have any questions, please email commentsPBAC@health.gov.au